SK27699A3 - (s)-7-[(4,4'-bipiperidin-1-yl)carbonyl]-2,3,4,5-tetrahydro-4- -methyl-3-oxo-1h-1,4-benzodiazepine-2-acetic acid, hydrochloride, processes for its preparation and methods for its use. - Google Patents

(s)-7-[(4,4'-bipiperidin-1-yl)carbonyl]-2,3,4,5-tetrahydro-4- -methyl-3-oxo-1h-1,4-benzodiazepine-2-acetic acid, hydrochloride, processes for its preparation and methods for its use. Download PDF

Info

Publication number: SK27699A3
Authority: SK; Slovakia
Prior art keywords: benzodiazepine; bipiperidin; oxo; methyl; tetrahydro
Prior art date: 1996-09-03

Application number

SK276-99A

Other languages

English (en)

Slovak (sk)

Inventor

Stephen T Ross

Original Assignee

Smithkline Beecham Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-09-03

Filing date

1997-08-29

Publication date

2000-02-14

1997-08-29 Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp

2000-02-14 Publication of SK27699A3 publication Critical patent/SK27699A3/sk

Links

VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 title claims abstract description 25
238000000034 method Methods 0.000 title claims abstract description 13
238000002360 preparation method Methods 0.000 title claims abstract description 11
PYZOVVQJTLOHDG-FQEVSTJZSA-N 2-[(2s)-4-methyl-3-oxo-7-(4-piperidin-4-ylpiperidine-1-carbonyl)-2,5-dihydro-1h-1,4-benzodiazepin-2-yl]acetic acid Chemical compound O=C([C@H](CC(O)=O)NC1=CC=2)N(C)CC1=CC=2C(=O)N(CC1)CCC1C1CCNCC1 PYZOVVQJTLOHDG-FQEVSTJZSA-N 0.000 title claims abstract description 10
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 21
-1 4,4'-bipiperidin-1-yl Chemical group 0.000 claims description 20
239000002253 acid Substances 0.000 claims description 15
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims description 14
239000008194 pharmaceutical composition Substances 0.000 claims description 9
208000010110 spontaneous platelet aggregation Diseases 0.000 claims description 9
230000002401 inhibitory effect Effects 0.000 claims description 5
238000002399 angioplasty Methods 0.000 claims description 4
201000010099 disease Diseases 0.000 claims description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
239000003937 drug carrier Substances 0.000 claims description 4
238000002844 melting Methods 0.000 claims description 4
230000008018 melting Effects 0.000 claims description 4
DUMCJIQEKVEWRJ-UHFFFAOYSA-N 2-(1,2-benzodiazepin-2-yl)acetic acid Chemical compound OC(=O)CN1C=CC=C2C=CC=CC2=N1 DUMCJIQEKVEWRJ-UHFFFAOYSA-N 0.000 claims description 3
241000124008 Mammalia Species 0.000 claims description 3
208000006011 Stroke Diseases 0.000 claims description 3
230000003287 optical effect Effects 0.000 claims description 3
208000005189 Embolism Diseases 0.000 claims description 2
208000007536 Thrombosis Diseases 0.000 claims description 2
208000010125 myocardial infarction Diseases 0.000 claims description 2
238000001953 recrystallisation Methods 0.000 claims description 2
230000002792 vascular Effects 0.000 claims description 2
206010061216 Infarction Diseases 0.000 claims 1
230000007574 infarction Effects 0.000 claims 1
238000005185 salting out Methods 0.000 claims 1
150000001875 compounds Chemical class 0.000 description 17
235000002639 sodium chloride Nutrition 0.000 description 17
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
150000003839 salts Chemical class 0.000 description 14
239000000243 solution Substances 0.000 description 14
239000002904 solvent Substances 0.000 description 13
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
238000007792 addition Methods 0.000 description 8
239000000203 mixture Substances 0.000 description 7
239000007787 solid Substances 0.000 description 7
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
239000002775 capsule Substances 0.000 description 4
239000000463 material Substances 0.000 description 4
108010012088 Fibrinogen Receptors Proteins 0.000 description 3
108010010803 Gelatin Proteins 0.000 description 3
229920000168 Microcrystalline cellulose Polymers 0.000 description 3
229920000881 Modified starch Polymers 0.000 description 3
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
239000002585 base Substances 0.000 description 3
239000000969 carrier Substances 0.000 description 3
238000002425 crystallisation Methods 0.000 description 3
230000008025 crystallization Effects 0.000 description 3
239000003814 drug Substances 0.000 description 3
239000003527 fibrinolytic agent Substances 0.000 description 3
239000008273 gelatin Substances 0.000 description 3
229920000159 gelatin Polymers 0.000 description 3
239000007903 gelatin capsule Substances 0.000 description 3
235000019322 gelatine Nutrition 0.000 description 3
235000011852 gelatine desserts Nutrition 0.000 description 3
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 3
229910000041 hydrogen chloride Inorganic materials 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
239000007788 liquid Substances 0.000 description 3
235000019359 magnesium stearate Nutrition 0.000 description 3
235000019813 microcrystalline cellulose Nutrition 0.000 description 3
239000008108 microcrystalline cellulose Substances 0.000 description 3
229940016286 microcrystalline cellulose Drugs 0.000 description 3
238000002156 mixing Methods 0.000 description 3
238000007911 parenteral administration Methods 0.000 description 3
239000000843 powder Substances 0.000 description 3
239000006188 syrup Substances 0.000 description 3
235000020357 syrup Nutrition 0.000 description 3
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
CLWDLBDPVUWYEW-UHFFFAOYSA-N 2-(4-methyl-3-oxo-2,5-dihydro-1h-1,4-benzodiazepin-2-yl)acetic acid Chemical compound N1C(CC(O)=O)C(=O)N(C)CC2=CC=CC=C21 CLWDLBDPVUWYEW-UHFFFAOYSA-N 0.000 description 2
IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
235000010643 Leucaena leucocephala Nutrition 0.000 description 2
240000007472 Leucaena leucocephala Species 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
206010000891 acute myocardial infarction Diseases 0.000 description 2
238000005054 agglomeration Methods 0.000 description 2
230000002776 aggregation Effects 0.000 description 2
239000005557 antagonist Substances 0.000 description 2
210000001367 artery Anatomy 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
239000013078 crystal Substances 0.000 description 2
239000008121 dextrose Substances 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 description 2
230000003480 fibrinolytic effect Effects 0.000 description 2
238000009472 formulation Methods 0.000 description 2
150000003840 hydrochlorides Chemical class 0.000 description 2
239000012535 impurity Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
239000012669 liquid formulation Substances 0.000 description 2
238000003801 milling Methods 0.000 description 2
239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
210000003462 vein Anatomy 0.000 description 2
SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
SXHPOBDTEYIZFL-UHFFFAOYSA-N 2-(1h-1,4-benzodiazepin-2-yl)acetic acid Chemical compound N1C(CC(=O)O)=CN=CC2=CC=CC=C21 SXHPOBDTEYIZFL-UHFFFAOYSA-N 0.000 description 1
ZTHSAEXVSBEBHE-BDQAORGHSA-N 2-[(2s)-4-methyl-3-oxo-7-(4-piperidin-4-ylpiperidine-1-carbonyl)-2,5-dihydro-1h-1,4-benzodiazepin-2-yl]acetic acid;hydrochloride Chemical compound Cl.O=C([C@H](CC(O)=O)NC1=CC=2)N(C)CC1=CC=2C(=O)N(CC1)CCC1C1CCNCC1 ZTHSAEXVSBEBHE-BDQAORGHSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
239000005695 Ammonium acetate Substances 0.000 description 1
206010002388 Angina unstable Diseases 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
239000005528 B01AC05 - Ticlopidine Substances 0.000 description 1
KBVSBOVOOFIRHG-UHFFFAOYSA-N CN1C(C(N=CC2=C1C=CC=C2)=O)CC(=O)O Chemical compound CN1C(C(N=CC2=C1C=CC=C2)=O)CC(=O)O KBVSBOVOOFIRHG-UHFFFAOYSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
206010051055 Deep vein thrombosis Diseases 0.000 description 1
208000002251 Dissecting Aneurysm Diseases 0.000 description 1
108010049003 Fibrinogen Proteins 0.000 description 1
102000008946 Fibrinogen Human genes 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
XGPUJAXMQQXPHC-UHFFFAOYSA-N N=1N(C=CC=C2C1C=CC=C2)CC(=O)O.Cl Chemical compound N=1N(C=CC=C2C1C=CC=C2)CC(=O)O.Cl XGPUJAXMQQXPHC-UHFFFAOYSA-N 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
208000010378 Pulmonary Embolism Diseases 0.000 description 1
102000007466 Purinergic P2 Receptors Human genes 0.000 description 1
108010085249 Purinergic P2 Receptors Proteins 0.000 description 1
206010040047 Sepsis Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
229940122388 Thrombin inhibitor Drugs 0.000 description 1
108010069102 Thromboxane-A synthase Proteins 0.000 description 1
208000007814 Unstable Angina Diseases 0.000 description 1
206010047249 Venous thrombosis Diseases 0.000 description 1
WJGAPUXHSQQWQF-UHFFFAOYSA-N acetic acid;hydrochloride Chemical compound Cl.CC(O)=O WJGAPUXHSQQWQF-UHFFFAOYSA-N 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
238000011360 adjunctive therapy Methods 0.000 description 1
239000008272 agar Substances 0.000 description 1
235000010419 agar Nutrition 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
229940043376 ammonium acetate Drugs 0.000 description 1
235000019257 ammonium acetate Nutrition 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
229940049706 benzodiazepine Drugs 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000013590 bulk material Substances 0.000 description 1
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
PASHVRUKOFIRIK-UHFFFAOYSA-L calcium sulfate dihydrate Chemical compound O.O.[Ca+2].[O-]S([O-])(=O)=O PASHVRUKOFIRIK-UHFFFAOYSA-L 0.000 description 1
230000002612 cardiopulmonary effect Effects 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
229960003009 clopidogrel Drugs 0.000 description 1
230000035602 clotting Effects 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
239000013065 commercial product Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000006184 cosolvent Substances 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
235000021438 curry Nutrition 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
229940126534 drug product Drugs 0.000 description 1
229940088679 drug related substance Drugs 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
238000010265 fast atom bombardment Methods 0.000 description 1
229940012952 fibrinogen Drugs 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000007789 gas Substances 0.000 description 1
239000011521 glass Substances 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
229940074045 glyceryl distearate Drugs 0.000 description 1
229940075507 glyceryl monostearate Drugs 0.000 description 1
238000000227 grinding Methods 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
208000026278 immune system disease Diseases 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
208000014674 injury Diseases 0.000 description 1
201000004332 intermediate coronary syndrome Diseases 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000003446 ligand Substances 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
238000001819 mass spectrum Methods 0.000 description 1
229940071648 metered dose inhaler Drugs 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
239000006199 nebulizer Substances 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
239000001814 pectin Substances 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
230000002980 postoperative effect Effects 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
239000002599 prostaglandin synthase inhibitor Substances 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
238000000926 separation method Methods 0.000 description 1
208000013223 septicemia Diseases 0.000 description 1
230000035939 shock Effects 0.000 description 1
239000003998 snake venom Substances 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
239000011343 solid material Substances 0.000 description 1
239000011877 solvent mixture Substances 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
238000003860 storage Methods 0.000 description 1
239000000829 suppository Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000000454 talc Substances 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
239000003868 thrombin inhibitor Substances 0.000 description 1
RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 1
229960005001 ticlopidine Drugs 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
230000008733 trauma Effects 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
229960005080 warfarin Drugs 0.000 description 1
PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Hematology (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

SK276-99A 1996-09-03 1997-08-29 (s)-7-[(4,4'-bipiperidin-1-yl)carbonyl]-2,3,4,5-tetrahydro-4- -methyl-3-oxo-1h-1,4-benzodiazepine-2-acetic acid, hydrochloride, processes for its preparation and methods for its use. SK27699A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US2536996P	1996-09-03	1996-09-03
PCT/US1997/015292 WO1998009629A1 (fr)	1996-09-03	1997-08-29	Produit pharmaceutique cristallin

Publications (1)

Publication Number	Publication Date
SK27699A3 true SK27699A3 (en)	2000-02-14

Family

ID=21825633

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK276-99A SK27699A3 (en)	1996-09-03	1997-08-29	(s)-7-[(4,4'-bipiperidin-1-yl)carbonyl]-2,3,4,5-tetrahydro-4- -methyl-3-oxo-1h-1,4-benzodiazepine-2-acetic acid, hydrochloride, processes for its preparation and methods for its use.

Country Status (32)

Country	Link
US (1)	US6335330B1 (fr)
EP (1)	EP0964684B1 (fr)
JP (1)	JP2000517342A (fr)
CN (1)	CN1102391C (fr)
AP (1)	AP9901472A0 (fr)
AR (1)	AR008154A1 (fr)
AT (1)	ATE245984T1 (fr)
AU (1)	AU731173B2 (fr)
BG (1)	BG103196A (fr)
BR (1)	BR9711981A (fr)
CA (1)	CA2264607A1 (fr)
CO (1)	CO4930262A1 (fr)
CZ (1)	CZ71999A3 (fr)
DE (1)	DE69723873T2 (fr)
DZ (1)	DZ2302A1 (fr)
EA (1)	EA001363B1 (fr)
ES (1)	ES2205254T3 (fr)
HU (1)	HUP9904077A3 (fr)
ID (1)	ID18156A (fr)
IL (1)	IL128782A0 (fr)
MA (1)	MA24309A1 (fr)
MY (1)	MY118175A (fr)
NO (1)	NO991013D0 (fr)
NZ (1)	NZ334438A (fr)
OA (1)	OA10986A (fr)
PE (1)	PE107198A1 (fr)
PL (1)	PL332006A1 (fr)
SK (1)	SK27699A3 (fr)
TR (1)	TR199900480T2 (fr)
UY (1)	UY24690A1 (fr)
WO (1)	WO1998009629A1 (fr)
ZA (1)	ZA977870B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19902529A1 (de) *	1999-01-22	2000-08-03	Goldwell Gmbh	Haarbehandlungsmittel
FR2797400A1 (fr) *	1999-08-11	2001-02-16	Sanofi Synthelabo	Associations a activite anti-thrombotique constituees de l'hydrogenosulfate de clopidogrel et d'un antagoniste des recepteurs gpiib/iiia et les compositions pharmaceutiques les contenant
EP1443963B1 (fr)	2001-10-22	2014-05-21	The Scripps Research Institute	Composes de ciblage d'anticorps
US20050202151A1 (en) *	2004-03-15	2005-09-15	Land O'lakes, Inc.	Method of preparing egg nuggets
KR101046977B1 (ko) *	2004-11-15	2011-07-07	삼성에스디아이 주식회사	카본나노튜브, 이를 포함한 전자 방출원 및 이를 구비한전자 방출 소자
US20070122408A1 (en) *	2005-10-20	2007-05-31	The Scripps Research Institute	Fc Labeling for Immunostaining and Immunotargeting
JP2012517447A (ja)	2009-02-10	2012-08-02	ザスクリプスリサーチインスティチュート	化学的にプログラムされたワクチン接種法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DD138319A1 (de) *	1978-08-08	1979-10-24	Helmut Roehnert	Verfahren zur herstellung einer stabilen,kristallwasser-und kristalloesungsmittelfreien kristallform des 7-chlor-2-methylamino-5-phenyl-3h-1,4-benzodiazepin-4-oxid-hydrochlorids
US5693636A (en)	1991-06-28	1997-12-02	Smithkline Beecham Corporation	Bicyclic fibrinogen antagonists
US5939412A (en)	1992-06-26	1999-08-17	Smithkline Beecham Corporation	Bicyclic fibrinogen antagonists
ES2197160T3 (es)	1992-12-21	2004-01-01	Smithkline Beecham Corp	Antagonistas fibronogeno bicicliclos.
MA23420A1 (fr) *	1994-01-07	1995-10-01	Smithkline Beecham Corp	Antagonistes bicycliques de fibrinogene.

1997
- 1997-08-29 MA MA24781A patent/MA24309A1/fr unknown
- 1997-08-29 TR TR1999/00480T patent/TR199900480T2/xx unknown
- 1997-08-29 NZ NZ334438A patent/NZ334438A/xx unknown
- 1997-08-29 CZ CZ99719A patent/CZ71999A3/cs unknown
- 1997-08-29 WO PCT/US1997/015292 patent/WO1998009629A1/fr not_active Ceased
- 1997-08-29 AP APAP/P/1999/001472A patent/AP9901472A0/en unknown
- 1997-08-29 AT AT97940707T patent/ATE245984T1/de not_active IP Right Cessation
- 1997-08-29 CA CA002264607A patent/CA2264607A1/fr not_active Abandoned
- 1997-08-29 CN CN97199135A patent/CN1102391C/zh not_active Expired - Fee Related
- 1997-08-29 JP JP10512762A patent/JP2000517342A/ja active Pending
- 1997-08-29 ES ES97940707T patent/ES2205254T3/es not_active Expired - Lifetime
- 1997-08-29 HU HU9904077A patent/HUP9904077A3/hu unknown
- 1997-08-29 BR BR9711981A patent/BR9711981A/pt not_active Application Discontinuation
- 1997-08-29 AR ARP970103966A patent/AR008154A1/es not_active Application Discontinuation
- 1997-08-29 DE DE69723873T patent/DE69723873T2/de not_active Expired - Lifetime
- 1997-08-29 EA EA199900260A patent/EA001363B1/ru not_active IP Right Cessation
- 1997-08-29 AU AU42425/97A patent/AU731173B2/en not_active Ceased
- 1997-08-29 PL PL97332006A patent/PL332006A1/xx unknown
- 1997-08-29 SK SK276-99A patent/SK27699A3/sk unknown
- 1997-08-29 US US09/254,305 patent/US6335330B1/en not_active Expired - Fee Related
- 1997-08-29 EP EP97940707A patent/EP0964684B1/fr not_active Expired - Lifetime
- 1997-08-29 IL IL12878297A patent/IL128782A0/xx unknown
- 1997-09-01 UY UY24690A patent/UY24690A1/es not_active IP Right Cessation
- 1997-09-01 CO CO97050462A patent/CO4930262A1/es unknown
- 1997-09-02 MY MYPI97004043A patent/MY118175A/en unknown
- 1997-09-02 ID IDP973061A patent/ID18156A/id unknown
- 1997-09-02 DZ DZ970152A patent/DZ2302A1/fr active
- 1997-09-02 ZA ZA9707870A patent/ZA977870B/xx unknown
- 1997-09-03 PE PE1997000779A patent/PE107198A1/es not_active Application Discontinuation
1999
- 1999-02-22 BG BG103196A patent/BG103196A/xx unknown
- 1999-03-02 NO NO991013A patent/NO991013D0/no not_active Application Discontinuation
- 1999-03-03 OA OA9900047A patent/OA10986A/en unknown

Also Published As

Publication number	Publication date
EA199900260A1 (ru)	1999-08-26
IL128782A0 (en)	2000-01-31
EP0964684B1 (fr)	2003-07-30
AP9901472A0 (en)	1999-03-31
BR9711981A (pt)	1999-08-24
NO991013L (no)	1999-03-02
CN1102391C (zh)	2003-03-05
OA10986A (en)	2003-03-04
DE69723873D1 (de)	2003-09-04
CZ71999A3 (cs)	1999-08-11
ATE245984T1 (de)	2003-08-15
MY118175A (en)	2004-09-30
BG103196A (en)	1999-09-30
HUP9904077A3 (en)	2002-03-28
ID18156A (id)	1998-03-05
AR008154A1 (es)	1999-12-09
CN1234739A (zh)	1999-11-10
US6335330B1 (en)	2002-01-01
NZ334438A (en)	2000-10-27
ES2205254T3 (es)	2004-05-01
UY24690A1 (es)	1998-02-27
JP2000517342A (ja)	2000-12-26
HUP9904077A2 (hu)	2000-05-28
CO4930262A1 (es)	2000-06-27
DE69723873T2 (de)	2004-04-22
MA24309A1 (fr)	1998-04-01
NO991013D0 (no)	1999-03-02
TR199900480T2 (xx)	1999-06-21
EP0964684A4 (fr)	2002-05-29
AU4242597A (en)	1998-03-26
DZ2302A1 (fr)	2002-12-28
PE107198A1 (es)	1999-03-21
EA001363B1 (ru)	2001-02-26
CA2264607A1 (fr)	1998-03-12
PL332006A1 (en)	1999-08-16
WO1998009629A1 (fr)	1998-03-12
AU731173B2 (en)	2001-03-22
EP0964684A1 (fr)	1999-12-22
ZA977870B (en)	1998-03-03

Publication	Publication Date	Title
JP2019135258A (ja)	2019-08-15	第Ｘａ因子阻害剤の結晶形態
JP2002510313A (ja)	2002-04-02	抗血栓物質
US20020004518A1 (en)	2002-01-10	Method of treating disorders related to protease-activated receptors-induced cell activation
HUT74103A (en)	1996-11-28	Aroyl-piperidine derivative
AU2982701A (en)	2001-10-04	Diazepan derivatives or salts thereof
CA2515102A1 (fr)	2004-08-19	Compositions pharmaceutiques comportant des derives thieno[2,3-c]pyridine et utilisation de ces compositions
JP5575979B2 (ja)	2014-08-20	シアノ基を含有するチエノピリジンエステル誘導体、その調製方法、使用および組成物
EP0964684B1 (fr)	2003-07-30	Produit pharmaceutique cristallin
US20210253550A1 (en)	2021-08-19	Therapeutic compounds and compositions
JPH0597674A (ja)	1993-04-20	コラーゲナーゼ阻害剤
MXPA99002118A (en)	1999-09-20	Crystalline pharmaceutical product
KR20000068406A (ko)	2000-11-25	결정질 제약 물질
CN112778371B (zh)	2024-01-30	一种噻吩并吡啶衍生物及其制备方法和用途
CA2476446A1 (fr)	2003-08-21	Utilisation d'inhibiteurs de l'antiporteur ions sodium-hydrogene pour le traitement de maladies thrombotiques et inflammatoires
KR20120053401A (ko)	2012-05-25	결정형 셀레콕십 함유 마이크로 복합 입자 및 이의 제조방법
JP3162587B2 (ja)	2001-05-08	新規複素環誘導体及び血小板凝集阻害剤
JPS5843919A (ja)	1983-03-14	抗血栓剤
JPH0753561A (ja)	1995-02-28	テトラヒドロチエノピリジン誘導体、その製造方法及び抗血球凝集剤
JPH08325229A (ja)	1996-12-10	新規なω−グアニジノ−Ｌ−α−アミノ酸アミド誘導体
KR20060125816A (ko)	2006-12-06	호중구증다 억제제
JP2002179694A (ja)	2002-06-26	リン酸エステル誘導体及び医薬組成物
JPH05255290A (ja)	1993-10-05	腫瘍壊死因子産生阻害剤
JPS62242621A (ja)	1987-10-23	抗血小板凝集剤
JPS639490B2 (fr)	1988-02-29
TW200812968A (en)	2008-03-16	Novel crystalline forms 2 639